Who is pushing for Phase 2 in lung fibrosis and who is pushing for Phase 2 in kidney fibrosis. How do you decide, why don't we have both. Rather than asking who is pushing which is unknowable we can always ask why i.e. given the available resources and with the share price languishing at an all time low, why is AdAlta planning Phase 2 clinical trials in two different disease indications?
Key data can be sourced in pre-clinical studies;
Anti-fibrotic effects of CXCR4- targeting i-body AD-114 in preclinical models of pulmonary fibrosis published February 2018. Read and inform your own view but my understanding is that AD-114 is a promising therapeutic for the treatment of pulmonary fibrosis due to its inhibition of invasive wound healing and collagen secretion and the amelioration of the degree of lung injury.
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4 published in January 2022. Again, read and inform your own view but my understanding is that AD-114 (and the second generation AD-214) is a promising therapeutic for the treatment of renal fibrosis due to its renoprotective role through the reduction of inflammatory cytokine and macrophage infiltration, mitigation of TGF-ß1 upregulation and suppression of fibroblast activation.
Here's the thing, according to the article New Aspects of Kidney Fibrosis - From Mechanisms of Injury to Modulation of Disease published in January 2022, the authors noted that fibrosis usually takes a similar course independent of the underlying organ disease.
The potential for AD-214 is off-the-charts even if AdAlta is yet another aussie biotech that is flying under-the-radar - just like Neuren in its formative clinical development phase.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)